Physician profile
Patrick H Waring
NPI 1346244019
$1,029.39
in general payments reported to CMS, 2019-2025
15 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $84.73 · 2021: $277 · 2022: $165 · 2023: $36.45 · 2024: $104 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $277.94 | 2020-2025 | Tirosint, Licart, Tirosint |
| Stryker Corporation | $163.39 | 2025 | Omnicurve, Spinejack, Mild Device Kit |
| Almatica Pharma LLC | $103.06 | 2021-2022 | |
| Abbott Laboratories | $99.50 | 2020-2021 | |
| Horizon Therapeutics Plc | $97.04 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $56.81 | 2021-2022 | |
| Assertio Therapeutics, INC. | $56.46 | 2019 | |
| Pfizer INC. | $46.08 | 2019-2021 | |
| Janssen Biotech, INC. | $34.62 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.00 | 2024 | Horizant |
| Alkermes, INC. | $16.95 | 2024 | Vivitrol |
| Kowa Pharmaceuticals America, INC. | $16.08 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.51 | 2025 | |
| Vertical Pharmaceuticals, LLC | $13.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Waring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.